GGrantIndex
← Leaderboards

Claudio A.p. Joazeiro

American Association For Cancer Research

$7,520,796
Attributed
$11,013,977
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $993.9K · FY200625
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,013,977 · 8

By mechanism

R01$10,957,352 · 4
P41$38,625 · 2
R13$18,000 · 2

Top collaborators

Others in their field

Top investigators on “Proteins

Research focus

ProteinsUbiquitin-Protein LigaseMutationBiochemicalBaseMediatingGenesCellsPathway InteractionsExhibitsReportingPolypeptideLeadStructureUbiquitinPost-Translational Protein ProcessingUbiquitinationMolecularResponseQuality ControlNovel TherapeuticsModificationMolecular GeneticsPlay

Grant awards (27)

Polyalanine Tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$735,524
R01 · FY2025 · NS
Polyalanine Tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$717,158
R01 · FY2024 · NS
Polyalanine Tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$732,174
R01 · FY2023 · NS
Polyalanine Tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$751,212
R01 · FY2022 · NS
FASEB SRC: The Ubiquitin & Ub-like proteins Conference: Cell Functions and Therapeutic Targeting$13,000
R13 · FY2022 · CA · contact PI
CAT-tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$662,384
R01 · FY2021 · NS
CAT-tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$662,384
R01 · FY2020 · NS
CAT-tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$659,497
R01 · FY2019 · NS
CAT-tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$659,497
R01 · FY2018 · NS
CAT-tails: A Novel Type of Protein Modification Implicated in Neurodegeneration$678,247
R01 · FY2017 · NS
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy$393,213
R01 · FY2016 · CA · contact PI
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration$378,984
R01 · FY2016 · NS · contact PI
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration$414,531
R01 · FY2015 · NS · contact PI
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy$393,213
R01 · FY2015 · CA · contact PI
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration$410,387
R01 · FY2014 · NS · contact PI
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy$381,417
R01 · FY2014 · CA · contact PI
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration$400,023
R01 · FY2013 · NS · contact PI
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy$369,620
R01 · FY2013 · CA · contact PI
A New E3 Ligase Implicated in Protein Quality Control and Neurodegeneration$414,531
R01 · FY2012 · NS · contact PI
Small Molecule Inhibitors of Mdm2 E3 Ubiquitin Ligase Activity for Cancer Therapy$393,213
R01 · FY2012 · CA · contact PI
MODULATION OF NF-kB ACTIVATION BY A NOVEL MITOCHONDRIAL E3 UBIQUITIN LIGASE$186,121
R01 · FY2012 · GM · contact PI
MODULATION OF NF-kB ACTIVATION BY A NOVEL MITOCHONDRIAL E3 UBIQUITIN LIGASE$186,121
R01 · FY2011 · GM · contact PI
STRUCTURE OF AN E3 LIGASE COMPLEX$25,707
P41 · FY2011 · RR · contact PI
MODULATION OF NF-kB ACTIVATION BY A NOVEL MITOCHONDRIAL E3 UBIQUITIN LIGASE$188,001
R01 · FY2010 · GM · contact PI
STRUCTURE OF AN E3 LIGASE COMPLEX$12,918
P41 · FY2010 · RR · contact PI
MODULATION OF NF-kB ACTIVATION BY A NOVEL MITOCHONDRIAL E3 UBIQUITIN LIGASE$189,900
R01 · FY2009 · GM · contact PI
Ubiquitin/Cancer:Molecular Targets/Mechanisms to Clinic$5,000
R13 · FY2006 · CA · contact PI